CMS To Stop Linking Payment For Aranesp, Procrit But Vows To Revisit Issue
Executive Summary
CMS remains open to aligning the payment rate for Amgen's Aranesp with Johnson & Johnson's Procrit in future years, although for now the agency is acting on its proposal to retire the "equitable adjustment" method for reimbursing the drugs
You may also be interested in...
EPO Analyses May Give J&J Fodder To Protect Procrit From Aranesp
Two recently released studies could help Johnson & Johnson in its efforts to ward off competition for its anemia therapy Procrit (epoetin) from Amgen's second-generation erythropoietin product Aranesp (darbepoetin)
Amgen’s Aranesp Reimbursement Continues To Get Scrutiny From Capitol Hill
The debate around Medicare reimbursement for Amgen's anemia treatments Aranesp and Epogen is being reopened by House Ways & Means Committee Chairman Bill Thomas (R-Calif.) as CMS drafts its annual payment update rule that addresses the issue
EPO Analyses May Give J&J Fodder To Protect Procrit From Aranesp
Two recently released studies could help Johnson & Johnson in its efforts to ward off competition for its anemia therapy Procrit (epoetin) from Amgen's second-generation erythropoietin product Aranesp (darbepoetin)